Psychopharmacology

, Volume 190, Issue 1, pp 103–115 | Cite as

Chronic fluoxetine increases cytosolic phospholipase A2 activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat

  • Ho-Joo Lee
  • Jagadeesh S. Rao
  • Renee N. Ertley
  • Lisa Chang
  • Stanley I. Rapoport
  • Richard P. Bazinet
Original Investigation

Abstract

Rationale

Fluoxetine is used to treat unipolar depression and is thought to act by increasing the concentration of serotonin (5-HT) in the synaptic cleft, leading to increased serotonin signaling. The 5-HT2A/2C receptor subtypes are coupled to a phospholipase A2 (PLA2). We hypothesized that chronic fluoxetine would increase the brain activity of PLA2 and the turnover rate of arachidonic acid (AA) in phospholipids of the unanesthetized rat.

Materials and methods

To test this hypothesis, rats were administered fluoxetine (10 mg/kg) or vehicle intraperitoneally daily for 21 days. In the unanesthetized rat, [1-14C]AA was infused intravenously and arterial blood plasma was sampled until the animal was killed at 5 min and its brain was subjected to chemical, radiotracer, or enzyme analysis.

Results

Using equations from our fatty acid model, we found that chronic fluoxetine compared with vehicle increased the turnover rate of AA within several brain phospholipids by 75–86%. The activity and protein levels of brain cytosolic PLA2 (cPLA2) but not of secretory or calcium-independent PLA2 were increased in rats administered fluoxetine. In a separate group of animals that received chronic fluoxetine followed by a 3-day saline washout, the turnover of AA and activity and protein levels of cPLA2 were not significantly different from controls. The protein levels of cyclooxygenases 1 and 2 as well as the concentration of prostaglandin E2 in rats chronically administered fluoxetine did not differ significantly from controls.

Conclusion

The results support the hypothesis that fluoxetine increases the cPLA2-mediated turnover of AA within brain phospholipids.

Keywords

Fluoxetine Brain Arachidonic acid Phospholipase A2 Cyclooxygenase Prostaglandin 

References

  1. Abou-Samra AB, Catt KJ, Aguilera G (1986) Biphasic inhibition of adrenocorticotropin release by corticosterone in cultured anterior pituitary cells. Endocrinology 119:972–977CrossRefPubMedGoogle Scholar
  2. Aveldano MI, VanRollins M, Horrocks LA (1983) Separation and quantitation of free fatty acids and fatty acid methyl esters by reverse phase high pressure liquid chromatography. J Lipid Res 24:83–93PubMedGoogle Scholar
  3. Axelrod J (1990) Receptor-mediated activation of phospholipase A2 and arachidonic acid release in signal transduction. Biochem Soc Trans 18:503–507CrossRefPubMedGoogle Scholar
  4. Barbour B, Szatkowski M, Ingledew N, Attwell D (1989) Arachidonic acid induces a prolonged inhibition of glutamate uptake into glial cells. Nature 342:918–920CrossRefPubMedGoogle Scholar
  5. Basselin M, Chang L, Seemann R, Bell JM, Rapoport SI (2003) Chronic lithium administration potentiates brain arachidonic acid signaling at rest and during cholinergic activation in awake rats. J Neurochem 85:1553–1562CrossRefPubMedGoogle Scholar
  6. Basselin M, Chang L, Bell JM, Rapoport SI (2005a) Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 31:1659–1674CrossRefPubMedGoogle Scholar
  7. Basselin M, Chang L, Seemann R, Bell JM, Rapoport SI (2005b) Chronic lithium administration to rats selectively modifies 5-HT2A/2C receptor-mediated brain signaling via arachidonic acid. Neuropsychopharmacology 30:461–472CrossRefPubMedGoogle Scholar
  8. Bazan NG (2005) Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol 32:89–103CrossRefPubMedGoogle Scholar
  9. Bazinet RP, Lee HJ, Felder CC, Porter AC, Rapoport SI, Rosenberger TA (2005a) Rapid high-energy microwave fixation is required to determine the anandamide (N-arachidonolylethanolamine) concentration of rat brain. Neurochem Res 30:597–601CrossRefPubMedGoogle Scholar
  10. Bazinet RP, Rao JS, Chang L, Rapoport SI, Lee HJ (2005b) Chronic valproate does not alter the kinetics of docosahexaenoic acid within brain phospholipids of the unanesthetized rat. Psychopharmacology (Berl) 182:180–185CrossRefGoogle Scholar
  11. Bazinet RP, Rao JS, Chang L, Rapoport SI, Lee HJ (2006a) Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol Psychiatry 59:401–407CrossRefPubMedGoogle Scholar
  12. Bazinet RP, Weis MT, Rapoport SI, Rosenberger TA (2006b) Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder. Psychopharmacology (Berl) 184:122–129CrossRefGoogle Scholar
  13. Benfield P, Heel RC, Lewis SP (1986) Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32:481–508CrossRefPubMedGoogle Scholar
  14. Berton O, Nestler EJ (2006) New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7:137–151CrossRefPubMedGoogle Scholar
  15. Bhattacharjee AK, Chang L, Lee HJ, Bazinet RP, Seemann R, Rapoport SI (2005) D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats. Psychopharmacology (Berl) 180:735–742CrossRefGoogle Scholar
  16. Borsch-Haubold AG, Bartoli F, Asselin J, Dudler T, Kramer RM, Apitz-Castro R, Watson SP, Gelb MH (1998) Identification of the phosphorylation sites of cytosolic phospholipase A2 in agonist-stimulated human platelets and HeLa cells. J Biol Chem 273:4449–4458CrossRefPubMedGoogle Scholar
  17. Bosetti F, Rintala J, Seemann R, Rosenberger TA, Contreras MA, Rapoport SI, Chang MC (2002) Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol Psychiatry 7:845–850CrossRefPubMedGoogle Scholar
  18. Bosetti F, Weerasinghe GR, Rosenberger TA, Rapoport SI (2003) Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J Neurochem 85:690–696CrossRefPubMedGoogle Scholar
  19. Bosetti F, Langenbach R, Weerasinghe GR (2004) Prostaglandin E2 and microsomal prostaglandin E synthase-2 expression are decreased in the cyclooxygenase-2-deficient mouse brain despite compensatory induction of cyclooxygenase-1 and Ca2+-dependent phospholipase A2. J Neurochem 91:1389–1397CrossRefPubMedGoogle Scholar
  20. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefPubMedGoogle Scholar
  21. Caccia S, Cappi M, Fracasso C, Garattini S (1990) Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl) 100:509–514CrossRefGoogle Scholar
  22. Cambronero JC, Rivas FJ, Borrell J, Guaza C (1992) Role of arachidonic acid metabolism on corticotropin-releasing factor (CRF)-release induced by interleukin-1 from superfused rat hypothalami. J Neuroimmunol 39:57–66CrossRefPubMedGoogle Scholar
  23. Chang MC, Grange E, Rabin O, Bell JM, Allen DD, Rapoport SI (1996) Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci Lett 220:171–174CrossRefPubMedGoogle Scholar
  24. Chang MC, Bell JM, Purdon AD, Chikhale EG, Grange E (1999) Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment. Neurochem Res 24:399–406CrossRefPubMedGoogle Scholar
  25. Chang MC, Contreras MA, Rosenberger TA, Rintala JJ, Bell JM, Rapoport SI (2001) Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem 77:796–803CrossRefPubMedGoogle Scholar
  26. Cunnane SC, Ryan MA, Nadeau CR, Bazinet RP, Musa-Veloso K, McCloy U (2003) Why is carbon from some polyunsaturates extensively recycled into lipid synthesis? Lipids 38:477–484CrossRefPubMedGoogle Scholar
  27. Damjanoska KJ, Van de Kar LD, Kindel GH, Zhang Y, D’Souza DN, Garcia F, Battaglia G, Muma NA (2003) Chronic fluoxetine differentially affects 5-hydroxytryptamine (2A) receptor signaling in frontal cortex, oxytocin- and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus. J Pharmacol Exp Ther 306:563–571CrossRefPubMedGoogle Scholar
  28. De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, Murray TK, Gaillard JP, Deville C, Xhenseval V, Thomas CE, O’Neill MJ, Zetterstrom TS (2004) Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 128:597–604CrossRefPubMedGoogle Scholar
  29. DeGeorge JJ, Noronha JG, Bell J, Robinson P, Rapoport SI (1989) Intravenous injection of [1-14C]arachidonate to examine regional brain lipid metabolism in unanesthetized rats. J Neurosci Res 24:413–423CrossRefPubMedGoogle Scholar
  30. DeMar JC Jr, Ma K, Bell JM, Rapoport SI (2004) Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids. J Neurochem 91:1125–1137CrossRefPubMedGoogle Scholar
  31. Deutsch J, Grange E, Rapoport SI, Purdon AD (1994) Isolation and quantitation of long-chain acyl-coenzyme A esters in brain tissue by solid-phase extraction. Anal Biochem 220:321–323CrossRefPubMedGoogle Scholar
  32. Deutsch J, Rapoport SI, Purdon AD (1997) Relation between free fatty acid and acyl-CoA concentrations in rat brain following decapitation. Neurochem Res 22:759–765CrossRefPubMedGoogle Scholar
  33. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W (1996) The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384:39–43CrossRefPubMedGoogle Scholar
  34. Dulawa SC, Holick KA, Gundersen B, Hen R (2004) Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29:1321–1330CrossRefPubMedGoogle Scholar
  35. Dumuis A, Pin JP, Oomagari K, Sebben M, Bockaert J (1990) Arachidonic acid released from striatal neurons by joint stimulation of ionotropic and metabotropic quisqualate receptors. Nature 347:182–184CrossRefPubMedGoogle Scholar
  36. Durand M, Berton O, Aguerre S, Edno L, Combourieu I, Mormede P, Chaouloff F (1999) Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis in SHR and WKY rats. Neuropharmacology 38:893–907CrossRefPubMedGoogle Scholar
  37. El Yacoubi M, Bouali S, Popa D, Naudon L, Leroux-Nicollet I, Hamon M, Costentin J, Adrien J, Vaugeois JM (2003) Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl Acad Sci USA 100:6227–6232CrossRefPubMedPubMedCentralGoogle Scholar
  38. Feder R (1990) Fluoxetine-induced mania. J Clin Psychiatry 51:524–525PubMedGoogle Scholar
  39. Felder CC, Kanterman RY, Ma AL, Axelrod J (1990) Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. Proc Natl Acad Sci USA 87:2187–2191CrossRefPubMedPubMedCentralGoogle Scholar
  40. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509PubMedGoogle Scholar
  41. Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:1871–1875CrossRefPubMedGoogle Scholar
  42. Garcia MC, Kim HY (1997) Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT2A receptor in rat C6 glioma cells. Brain Res 768:43–48CrossRefPubMedGoogle Scholar
  43. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK (2003) Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 5:421–433CrossRefPubMedGoogle Scholar
  44. Ghelardoni S, Tomita YA, Bell JM, Rapoport SI, Bosetti F (2004) Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol Psychiatry 56:248–254CrossRefPubMedGoogle Scholar
  45. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM (2004) Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 161:1537–1547CrossRefPubMedGoogle Scholar
  46. Goodwin GM (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17:149–173, discussion 147CrossRefPubMedGoogle Scholar
  47. Grange E, Deutsch J, Smith QR, Chang M, Rapoport SI, Purdon AD (1995) Specific activity of brain palmitoyl-CoA pool provides rates of incorporation of palmitate in brain phospholipids in awake rats. J Neurochem 65:2290–2298CrossRefPubMedGoogle Scholar
  48. Hefner Y, Borsch-Haubold AG, Murakami M, Wilde JI, Pasquet S, Schieltz D, Ghomashchi F, Yates JR 3rd, Armstrong CG, Paterson A, Cohen P, Fukunaga R, Hunter T, Kudo I, Watson SP, Gelb MH (2000) Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. J Biol Chem 275:37542–37551CrossRefPubMedGoogle Scholar
  49. Hertz R, Magenheim J, Berman I, Bar-Tana J (1998) Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4alpha. Nature 392:512–516CrossRefPubMedGoogle Scholar
  50. Koide H, Ogita K, Kikkawa U, Nishizuka Y (1992) Isolation and characterization of the epsilon subspecies of protein kinase C from rat brain. Proc Natl Acad Sci USA 89:1149–1153CrossRefPubMedPubMedCentralGoogle Scholar
  51. Kucia K, Malecki A, Gabryel B, Trzeciak HI (2003) Effect of antidepressants on the phospholipase A2 activity in plasma membranes of the rat brain cortex. Pol J Pharmacol 55:5–15PubMedGoogle Scholar
  52. Kuehl FA Jr, Humes JL (1972) Direct evidence for a prostaglandin receptor and its application to prostaglandin measurements (rat–adipocytes–antagonists–analogues–mouse ovary assay). Proc Natl Acad Sci USA 69:480–484CrossRefPubMedPubMedCentralGoogle Scholar
  53. Kuehl FA Jr, Humes JL, Tarnoff J, Cirillo VJ, Ham EA (1970) Prostaglandin receptor site: evidence for an essential role in the action of luteinizing hormone. Science 169:883–886CrossRefPubMedGoogle Scholar
  54. Lands WEM, Crawford CG (1976) Enzymes of membrane phospholipid metabolism. In: Marinosi A (ed) The enzyme of biological membrane. pp 3–85Google Scholar
  55. Lee HJ, Ghelardoni S, Chang L, Bosetti F, Rapoport SI, Bazinet RP (2005) Topiramate does not alter the kinetics of arachidonic or docosahexaenoic acid in brain phospholipids of the unanesthetized rat. Neurochem Res 30:677–683CrossRefPubMedGoogle Scholar
  56. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Kupka RW, Denicoff KD, Nolen WA, Grunze H, Martinez MI, Post RM (2006) Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 163:232–239CrossRefPubMedGoogle Scholar
  57. Lucas KK, Dennis EA (2005) Distinguishing phospholipase A2 types in biological samples by employing group-specific assays in the presence of inhibitors. Prostaglandins Other Lipid Mediat 77:235–248CrossRefPubMedGoogle Scholar
  58. MacDonald JI, Sprecher H (1991) Phospholipid fatty acid remodeling in mammalian cells. Biochim Biophys Acta 1084:105–121CrossRefPubMedGoogle Scholar
  59. Makrides M, Neumann MA, Byard RW, Simmer K, Gibson RA (1994) Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr 60:189–194PubMedGoogle Scholar
  60. Mercier G, Lennon AM, Renouf B, Dessouroux A, Ramauge M, Courtin F, Pierre M (2004) MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 24:207–216CrossRefPubMedGoogle Scholar
  61. Miller B, Sarantis M, Traynelis SF, Attwell D (1992) Potentiation of NMDA receptor currents by arachidonic acid. Nature 355:722–725CrossRefPubMedGoogle Scholar
  62. Mulligan SJ, MacVicar BA (2004) Calcium transients in astrocyte endfeet cause cerebrovascular constrictions. Nature 431:195–199CrossRefPubMedGoogle Scholar
  63. Murphy EJ, Owada Y, Kitanaka N, Kondo H, Glatz JF (2005) Brain arachidonic acid incorporation is decreased in heart fatty acid binding protein gene-ablated mice. Biochemistry 44:6350–6360CrossRefPubMedGoogle Scholar
  64. Nariai T, DeGeorge JJ, Greig NH, Genka S, Rapoport SI, Purdon AD (1994) Differences in rates of incorporation of intravenously injected radiolabeled fatty acids into phospholipids of intracerebrally implanted tumor and brain in awake rats. Clin Exp Metastasis 12:213–225CrossRefPubMedGoogle Scholar
  65. Nierenberg AA (2001) Do some antidepressants work faster than others? J Clin Psychiatry 62(Suppl 15):22–25PubMedGoogle Scholar
  66. Patrick CB, McHowat J, Rosenberger TA, Rapoport SI, Murphy EJ (2005) Arachidonic acid incorporation and turnover is decreased in sympathetically denervated rat heart. Am J Physiol Heart Circ Physiol 288:H2611–H2619CrossRefPubMedGoogle Scholar
  67. Purdon D, Arai T, Rapoport S (1997) No evidence for direct incorporation of esterified palmitic acid from plasma into brain lipids of awake adult rat. J Lipid Res 38:526–530PubMedGoogle Scholar
  68. Qu Y, Chang L, Klaff J, Balbo A, Rapoport SI (2003a) Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (+/-)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI). Neuropsychopharmacology 28:244–252CrossRefPubMedGoogle Scholar
  69. Qu Y, Chang L, Klaff J, Seemann R, Rapoport SI (2003b) Imaging brain phospholipase A2-mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats. Neuropsychopharmacology 28:1219–1226CrossRefPubMedGoogle Scholar
  70. Qu Y, Villacreses N, Murphy DL, Rapoport SI (2005) 5-HT2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter. Psychopharmacology (Berl) 180:12–20CrossRefGoogle Scholar
  71. Qu Y, Chang L, Klaff J, Seemann R, Greenstein D, Rapoport SI (2006) Chronic fluoxetine upregulates arachidonic acid incorporation into the brain of unanesthetized rats. Eur Neuropsychopharmacol (in press)Google Scholar
  72. Radin NS (1981) Extraction of tissue lipids with a solvent of low toxicity. Methods Enzymol 72:5–7CrossRefPubMedGoogle Scholar
  73. Rao JS, Rapoport SI, Bosetti F (2005) Decrease in the AP-2 DNA-binding activity and in the protein expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated with lithium for 6 weeks. Neuropsychopharmacology 30:2006–2013CrossRefPubMedGoogle Scholar
  74. Rao JS, Ertley RN, Lee HJ, Rapoport SI, Bazinet RP (2006) Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex. Pharmacogenomics J (in press). DOI 10.1038/sj.tpj.6500391
  75. Rapoport SI, Bosetti F (2002) Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 59:592–596CrossRefPubMedGoogle Scholar
  76. Rapoport SI, Chang MC, Spector AA (2001) Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res 42:678–685PubMedGoogle Scholar
  77. Rintala J, Seemann R, Chandrasekaran K, Rosenberger TA, Chang L, Contreras MA, Contreras MA, Rapoport SI, Chang MC (1999) 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport 10:3887–3890CrossRefPubMedGoogle Scholar
  78. Robinson PJ, Noronha J, DeGeorge JJ, Freed LM, Nariai T, Rapoport SI (1992) A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis. Brain Res Brain Res Rev 17:187–214CrossRefPubMedGoogle Scholar
  79. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237:1171–1176CrossRefPubMedGoogle Scholar
  80. Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191–1197CrossRefPubMedGoogle Scholar
  81. Shimizu T, Wolfe LS (1990) Arachidonic acid cascade and signal transduction. J Neurochem 55:1–15CrossRefPubMedGoogle Scholar
  82. Skipski VP, Good JJ, Barclay M, Reggio RB (1968) Quantitative analysis of simple lipid classes by thin-layer chromatography. Biochim Biophys Acta 152:10–19CrossRefPubMedGoogle Scholar
  83. Stout BD, Clarke WP, Berg KA (2002) Rapid desensitization of the serotonin(2C) receptor system: effector pathway and agonist dependence. J Pharmacol Exp Ther 302:957–962CrossRefPubMedGoogle Scholar
  84. Tay A, Maxwell P, Li ZG, Goldberg H, Skorecki K (1994) Cytosolic phospholipase A2 gene expression in rat mesangial cells is regulated post-transcriptionally. Biochem J 304(Pt 2):417–422CrossRefPubMedPubMedCentralGoogle Scholar
  85. Tohen M, Risser R (2005) Olanzapine and olanzapine–fluoxetine combination treatment and bipolar I depression—reply. Arch Gen Psychiatry 62:1052CrossRefGoogle Scholar
  86. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A (2003) Efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079–1088CrossRefPubMedGoogle Scholar
  87. Washizaki K, Smith QR, Rapoport SI, Purdon AD (1994) Brain arachidonic acid incorporation and precursor pool specific activity during intravenous infusion of unesterified [3H]arachidonate in the anesthetized rat. J Neurochem 63:727–736CrossRefPubMedGoogle Scholar
  88. Wijendran V, Lawrence P, Diau GY, Boehm G, Nathanielsz PW, Brenna JT (2002) Significant utilization of dietary arachidonic acid is for brain adrenic acid in baboon neonates. J Lipid Res 43:762–767PubMedGoogle Scholar
  89. Wong DT, Perry KW, Bymaster FP (2005) Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov 4:764–774PubMedGoogle Scholar
  90. Yang HC, Mosior M, Johnson CA, Chen Y, Dennis EA (1999a) Group-specific assays that distinguish between the four major types of mammalian phospholipase A2. Anal Biochem 269:278–288CrossRefPubMedGoogle Scholar
  91. Yang HC, Mosior M, Ni B, Dennis EA (1999b) Regional distribution, ontogeny, purification, and characterization of the Ca2+-independent phospholipase A2 from rat brain. J Neurochem 73:1278–1287CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Ho-Joo Lee
    • 1
  • Jagadeesh S. Rao
    • 1
  • Renee N. Ertley
    • 1
  • Lisa Chang
    • 1
  • Stanley I. Rapoport
    • 1
  • Richard P. Bazinet
    • 1
    • 2
  1. 1.Brain Physiology and Metabolism Section National Institute on AgingNational Institutes of HealthBethesdaUSA
  2. 2.Faculty of MedicineDepartment of Nutritional Sciences, University of TorontoTorontoCanada

Personalised recommendations